REYKJAVIK, ICELAND & PARSIPPANY, NJ - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
(NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn's disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis.
“We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.
S. Market Access at Teva.“Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI's launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.
S. market. We will be working with payors to ensure access to SIMLANDI, as well as the six other biosimilars we are committed to bringing to market by 2027.
” SIMLANDI is approved by the U.S. Food and Drug Administration (FDA) as the first high-concentration, citrate-free biosimilar to Humira with interchangeability exclusivity for the 40mg/0.
4mL injection. While both low-concentration and high-concentration strength biosimilars of Humira are marketed in the U.S.
today, nearly 88 percent of U.S. prescriptions for adalimumab are for the high-concentration presentatio.
